文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

Sotatercept联合长期扩展治疗较低危骨髓增生异常综合征患者贫血:一项2期剂量探索试验

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
PubMed 文献 · Lancet Haematol · 2018-01-10

这项开放标签、多中心、剂量探索2期试验纳入74例较低危骨髓增生异常综合征伴贫血且促红细胞生成素刺激剂治疗失败或不适合的患者,评估Sotatercept的安全性和有效性。结果显示49%的患者达到血液学改善-红系,最常见不良事件为疲劳(26%)和外周水肿(24%),3-4级治疗中出现不良事件发生率为34%。作者认为Sotatercept耐受性良好且有效,可能对这些治疗选择有限的患者有益。

要点

  • 74例较低危MDS伴贫血患者中,36例(49%;95%CI 38-60)达到血液学改善-红系。
  • 高输血负荷患者中29/62例(47%;95%CI 35-59)达到HI-E,低输血负荷患者中7/12例(58%;95%CI 32-81)达到HI-E。
  • 最常见不良事件为疲劳19例(26%)和外周水肿18例(24%),3-4级治疗中出现不良事件25例(34%)。

核心结论

  • Sotatercept是一种新型激活素受体融合蛋白,在既往ESA治疗失败的较低危MDS患者中耐受性良好且对贫血有效。
  • 作者认为Sotatercept治疗可能对这些治疗选择有限的患者有益。

研究设计与样本

  • 开放标签、多中心、剂量探索2期试验,在美国和法国的11个治疗中心开展。
  • 纳入年龄≥18岁、IPSS定义的低危或中危-1骨髓增生异常综合征、需要红细胞输注的贫血、不适合或对促红细胞生成素刺激剂难治的患者。
  • 排除无来那度胺治疗失败记录的染色体5q缺失骨髓增生异常综合征患者。
  • 患者随机接受0.1或0.3 mg/kg sotatercept皮下注射,采用置换区组法并按血清促红细胞生成素浓度和输血负荷分层;0.5、1.0和2.0 mg/kg组为非随机分配。
  • 2012年12月5日至2015年7月22日共入组74例患者(0.1 mg/kg组7例、0.3 mg/kg组6例、0.5 mg/kg组21例、1.0 mg/kg组35例、2.0 mg/kg组5例)。

主要发现

  • 74例患者中36例(49%;95%CI 38-60)达到HI-E。
  • 高输血负荷的62例患者中29例(47%;95%CI 35-59)达到HI-E,定义为红细胞输注较基线减少≥4单位持续至少56天。
  • 低输血负荷的12例患者中7例(58%;95%CI 32-81)达到HI-E,定义为无输血情况下血红蛋白升高≥1.5 g/dL持续至少56天。
  • 最常见不良事件为疲劳19例(26%)和外周水肿18例(24%)。
  • 3-4级治疗中出现不良事件25例(34%),其中4例(5%)被认为与治疗相关;最常见3-4级治疗中出现不良事件为脂肪酶升高和贫血,各3例(4%)。

关键数值与推荐

  • 主要疗效终点为按国际工作组2006标准达到血液学改善-红系(HI-E)的患者比例。
  • 高输血负荷患者HI-E定义为红细胞输注较基线减少≥4单位持续至少56天。
  • 低输血负荷患者HI-E定义为无输血情况下血红蛋白升高≥1.5 g/dL持续至少56天。
  • 用法为sotatercept 0.1或0.3 mg/kg皮下注射(随机),0.5、1.0、2.0 mg/kg为非随机分配。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为Sotatercept治疗可能对既往ESA治疗失败的较低危MDS贫血患者有益,这些患者治疗选择有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis leading to anaemia. Sotatercept (ACE-011) is a novel activin receptor type IIA fusion protein that acts as a ligand trap to neutralise negative regulators of late-stage erythropoiesis. The aim of the study was to establish a safe and effective dose of sotatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes. METHODS: This open-label, multicentre, dose-ranging, phase 2 trial took place at 11 treatment centres in the USA and France. Eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low-risk or intermediate-1-risk myelodysplastic syndromes, had anaemia requiring red blood cell (RBC) transfusions, and were ineligible for, or refractory to, erythropoiesis-stimulating agents (ESAs). Patients were not eligible if they had chromosome 5q deletion myelodysplastic syndromes without documented failure of lenalidomide. Patients were randomly assigned to receive either 0·1 or 0·3 mg/kg sotatercept subcutaneously, using a permuted-block method with stratification for serum erythropoietin concentration and transfusion burden. Patients were assigned to 0·5, 1·0, and 2·0 mg/kg groups in a non-randomised fashion. The primary efficacy endpoint was the proportion of patients who achieved haematological improvement-erythroid (HI-E), according to International Working Group 2006 criteria. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, number NCT01736683 and at EU Clinical Trials Register, number 2012-002601-22, and is ongoing. FINDINGS: Between Dec 5, 2012, and July 22, 2015, 74 patients were enrolled into the study (seven to receive 0·1 mg/kg sotatercept, six to 0·3 mg/kg, 21 to 0·5 mg/kg, 35 to 1·0 mg/kg, and five to 2·0 mg/kg). 36 (49%; 95% CI 38-60) of 74 patients achieved HI-E; 29 (47%; 95% CI 35-59) of 62 patients with a high transfusion burden achieved HI-E (RBC-transfusion reduction from baseline of 4 or more units for at least 56 days), and seven (58%; 95% CI 32-81) of 12 patients with a low transfusion burden achieved HI-E (haemoglobin increase of 1·5 g/dL or more sustained for at least 56 days in the absence of transfusions). The most commonly reported adverse events were fatigue in 19 (26%) of 74 patients and peripheral oedema in 18 (24%) of 74 patients. Grade 3-4 treatment-emergent adverse events (TEAEs) were reported in 25 (34%) of 74 patients; four (5%) patients had grade 3-4 TEAEs that were considered to be treatment related. The most common grade 3-4 TEAEs were lipase increase and anaemia, which each occurred in three (4%) of 74 patients. 17 (23%) of 74 patients had at least one serious TEAE, and one patient died from a treatment-emergent subdural haematoma due to a fall. INTERPRETATION: Sotatercept, a novel activin-receptor fusion protein, was well tolerated and effective for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes in whom previous ESA treatment had failed. Treatment with sotatercept could be beneficial for these patients who have few available treatment options. FUNDING: Celgene Corporation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018. PMID: 29331635. doi:10.1016/S2352-3026(18)30002-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。